Patents by Inventor Brian J. Hare

Brian J. Hare has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating APOL-1 dependent focal segmental glomerulosclerosis
    Patent number: 11801234
    Abstract: This application describes methods of inhibiting APOL1 and treating APOL1-mediated kidney diseases comprising administering Compound I and/or a pharmaceutically acceptable salt thereof. The application also describes pharmaceutical compositions comprising Compound I and/or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 5, 2021
    Date of Patent: October 31, 2023
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Navita Mallalieu, Ifeatu Egbuna, Brian J. Hare, Alexander Wolfgang Krug, Shu-Pei Wu
  • METHODS OF TREATMENT FOR CYSTIC FIBROSIS
    Publication number: 20220047564
    Abstract: This application describes methods of treating cystic fibrosis or a CFTR mediated disease comprising administering Compound I or a pharmaceutically acceptable salt thereof. (I) The application also describes pharmaceutical compositions comprising Compound I or a pharmaceutically acceptable salt thereof and optionally comprising one or more additional CFTR modulating agents.
    Type: Application
    Filed: November 13, 2019
    Publication date: February 17, 2022
    Inventors: David M. ALTSHULER, Corey Don ANDERSON, Bartlomiej BOREK, Weichao George CHEN, Jeremy J. CLEMENS, Thomas CLEVELAND, Timothy Richard COON, Bryan FRIEMAN, Peter GROOTENHUIS, Sara Sabina HADIDA RUAH, Brian J. HARE, Reshma KEWALRAMANI, Jason McCARTNEY, Mark Thomas MILLER, Prasuna PARASELLI, Fabrice PIERRE, Sarah M. ROBERTSON, Patrick R. SOSNAY, Sara E. SWIFT, Fredrick VAN GOOR, Tim YOUNG, Jinglan ZHOU
  • METHODS OF TREATING APOL-1 DEPENDENT FOCAL SEGMENTAL GLOMERULOSCLEROSIS
    Publication number: 20210275496
    Abstract: This application describes methods of inhibiting APOL1 and treating APOL1-mediated diseases comprising administering Compound I and/or a pharmaceutically acceptable salt thereof. The application also describes pharmaceutical compositions comprising Compound I and/or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 5, 2021
    Publication date: September 9, 2021
    Inventors: Navita Mallalieu, Ifeatu Egbuna, Brian J. Hare, Alexander Wolfgang Krug, Shu-pei Wu
  • METHODS OF TREATMENT FOR ALPHA-1 ANTITRYPSIN DEFICIENCY
    Publication number: 20210260036
    Abstract: This application describes methods of treating alpha-1 antitrypsin deficiency (AATD) comprising administering Compound I, a deuterated derivative thereof, and/or a pharmaceutically acceptable salt thereof. The application also describes pharmaceutical compositions comprising Compound I, a deuterated derivative thereof, and/or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 29, 2021
    Publication date: August 26, 2021
    Inventors: Carmen BOZIC, Brenda CIRINCIONE, Brian J. HARE, Edward INGENITO, Sanjeev KUMAR, Gautham MARIGOWDA, Porntula PANORCHAN, Mark Christopher PETERSON, David RHEE, David Kent STILES, Bosheng TIAN, Weiyan ZHANG
  • HEPATITIS C VIRUS INFECTION BIOMARKERS
    Publication number: 20100028874
    Abstract: A signature set of genes associated with hepatitis C virus infection is described.
    Type: Application
    Filed: April 25, 2007
    Publication date: February 4, 2010
    Inventors: Ravi K. Ramachandran, Matthew W. Harding, Paul R. Caron, Martyn C. Botfield, Brian J. Hare, Raj Bandaru, Kevin M. Kelliher, Catharine N. Cornell